Sur cette page
Publications
See current publications list at PubMed.
See Research Gate profile.
Selected publications:
- Malhotra N, Abunassar J,. Wells GA, McPherson R, Fu A, Hibbert B, Labinaz M, Le May M, Dick A, Glover C, Froeschl M, Marquis JF, Tran L, Bernick J, Chong AY, So D. on behalf of the CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators. A Pharmacodynamic Comparison of a Personalized Strategy for Anti-platelet Therapy versus Ticagrelor in Achieving a Therapeutic Window. Int J Cardiol. 2015.
- So DY, Wells GA, McPherson R, Labinaz M, Le May MR, Glover C, Dick AJ, Froeschl M, Marquis JF, Gollob MH, Tran L, Bernick J, Hibbert B, Roberts JD on behalf of the CAPITAL investigators. A Prospective Randomized Evaluation of a Pharmacogenomic Approach to Antiplatelet Therapy among Patients with ST-Elevation Myocardial Infarction: The RAPID STEMI Study. Pharmacogenomics J. 2015 Apr
- Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O’Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DYF. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial. The Lancet. 2012 May 5; 379(9827):1705-11.
- So DYF, Roberts, JD. Overcoming Obstacles in Pharmacogenomic Strategies for Antiplatelet Drugs – Are We RAPID enough? Pharmacogenomics. July 2012; 13(10):1105-8.
- Goncalves SC, Labinaz M, Le May M, Glover C, Froeschl M, Marquis JF, O'Brien E, Shukla D, Ruchin P, Sookur D, Ha A, So D. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol. 2011 Jan 15;107(2):204-9.
- So DY, Cook EF, Le May M, Glover C, Williams W, Ha A, Davie RF, Froeschl M, Marquis JF, O’Brien E, Labinaz M. Association of Aspirin Dosage to Clinical Outcomes after Percutaneous Coronary Intervention: Observations from the Ottawa Heart Institute PCI Registry. J Invasive Cardiol. 2009. 21(3):121-7.
- Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, Davies RF, Sherrard HL, Maloney J, Marquis JF, O’Brien ER, Trickett J, Poirer P, Ryan SC, Ha A, Joseph PG, Labinaz M. A Citywide Protocol for Primary PCI in ST-segment Elevation Myocardial Infarction. New Engl J Medicine. 2008. 358(3):231-40
Personnel
Current Team Members
Team Leader:
Derek So, MD, Interventional Cardiology
Members:
Aun Yeong Chong, MD, Interventional Cardiology
Benjamin Hibbert, MD, Interventional Cardiology
Michel Le May, MD, Interventional Cardiology
Marino Labinaz, MD, Interventional Cardiology
Chris Glover, MD, Interventional Cardiology
Ruth McPherson, MD, PhD, Genetics and Atherogenomics
George A. Wells, PhD, Epidemiology
Fraser Rubens, MD, Cardiac Surgery
Marc Ruel, MD, Cardiac Surgery
Vincent Chan, MD, Cardiac Surgery
Jean-Yves Dupuis, MD, Anesthesia
Michael Bourke, MD, Anesthesia
Research Assistants and Coordinators:
Lyne Stuewe (RN) – Nurse Coordinator
Cheryl Charlebois (RN) – Nurse Coordinator
Colleen Chilton (RN) – Nurse Coordinator
Research Fellows:
Kuljit Singh, MD
Collaborating Investigators
Jean-François Tanguay. MD (Interventional Cardiology, Montreal Heart Institute)
Marie Lordkipanidze, MD (Pharmacology, Montreal Heart Institute)
Louis Perrault, MD (Cardiac Surgery, Montreal Heart Institute)
Previous Research Fellows
Joseph Abunassar, MD – Johns Hopkins University
Ali Pourdjabbar, MD – University of San Diego
Jason Roberts, MD – Western University
Sandro Goncalves, MD – Federal University of Rio Grande do Sul
Projets
A Randomized Pilot Vanguard Study of Patients with ACS Treated with Ticagrelor Requiring Coronary Artery Bypass Surgery
(RAPID TITRATE CABG) – recruitment to start fall 2015:
- Multi-centred randomized study at the University of Ottawa Heart Institute and the Montreal Heart Institute
- Comparison of an early vs. delayed approach to CABG among ACS patients initially treated with ticagrelor
- Primary outcome: feasibility and safety of an early CABG strategy (with clinical outcomes to be used in a future large scale multi-centred study)
- Key secondary outcomes: platelet function testing for evaluation of mechanisms of benefits of an early CABG strategy
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition versus Ticagrelor in Reducing Ischemic and Bleeding Risk
(RAPID MANAGE – Clinicaltrials.gov: NCT02044146) - recruiting:
- Multi-centred randomized study at the University of Ottawa Heart Institute and the Montreal Heart Institute
- Comparison of novel personalized strategy (combining pharmacogenomics [CYP2C19*2, *3] and demographic factors to identify patients at high risk for high on-treatment platelet reactivity) vs. ticagrelor in patients with NSTE-ACS
- Primary outcome: proportion of patients achieving therapeutic window as measured by VerifyNow P2Y12 assay (PRU between 82 and 208)
- Key secondary outcomes: therapeutic window measured with Aggredyne and multiplate platelet assays
Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?
(OPTICROSS – clinicaltrials.gov: NCT02054663) – recruitment completed:
- Randomized study to evaluate optimal strategy to transition between ticagrelor to clopidogrel among patients with ACS requiring a switch from ticagrelor to clopidogrel
- Primary outcome: PRU measured (by VerifyNow P2Y12 assay) at 72 hours after initiation of strategy
- Key secondary outcomes: high on-treatment platelet reactivity in first 72 hours
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients with ST-Elevation Myocardial Infarction (RAPID STEMI)
– completed. Pharmacogenomics J. 2015 Apr
- Randomized study evaluating a pharmacgenomic strategy in patients with STEMI
- Patients randomized to high-dose clopidogrel vs. personalized strategy (carriers of CYP2C19*2, ABCB1TT switched to prasugrel, while non-carriers continued with clopidogrel). Proof-of-concept to identify 3 genetic variants concurrently (CYP2C19*2,*17 and ABCB1TT).
- Primary outcome: proportion with high on-treatment platelet reactivity at 1 month
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy based on GENetic Evaluation (RAPID GENE)
– completed. Lancet. 2012 May 5; 379(9827):1705-11. Epub 2012 Mar 29.
- Design and proof-of-concept of the first bedside genetic test in clinical medicine
- Randomized study of patients with stable CAD or NSTE-ACS undergoing PCI
- Patients randomized to standard therapy vs. personalized approach (carriers of CYP2C19*2 switched to prasugrel)
- Primary outcome: proportion with high on-treatment platelet reactivity at 1 week
The above studies utilize our state-of-the-art pharmacogenomics and platelet function laboratory, which uniquely is one of two institutions in Canada with the capabilities to perform these tests.
Offres d'emploi
Opportunities:
To enquire about available positions, please submit your CV with a cover letter detailing what you can bring to the team.
Contact:
@email